ROSETTA GENOMICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | +9,900.00% |
|
-.--% | -.--% |
| 2018 | Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd.. | CI |
| 2018 | Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index | CI |
| Sales 2015 | 8.27M 689M | Sales 2016 | 9.23M 770M | Capitalization | 9.22M 769M |
|---|---|---|---|---|---|
| Net income 2015 | -17M -1.42B | Net income 2016 | -16M -1.33B | EV / Sales 2015 | 1.07 x |
| Net cash position 2015 | 13.54M 1.13B | Net cash position 2016 | 2.45M 204M | EV / Sales 2016 | 0.73 x |
| P/E ratio 2015 |
-1.07
x | P/E ratio 2016 |
-0.54
x | Employees | 86 |
| Yield 2015 * |
-
| Yield 2016 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | +9,900.00% |
Current year
0.00
0.00
1 year
0.000.00
3 years
0.000.11
5 years
0.000.39
10 years
0.0066.60
| Managers | Title | Age | Since |
|---|---|---|---|
Ron Kalfus
DFI | Director of Finance/CFO | 50 | 24/12/24 |
Nicole Massoll
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Sidransky
BRD | Director/Board Member | 64 | 22/09/22 |
Rosetta Genomics Ltd. is an Israel-based company engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA), and protein biomarkers, and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). The Company is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The Company's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The Company focuses on developing a diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 592 | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ROSGQ Stock
